Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio5.43
Quick Ratio5.43
Price-To-Earnings
Trailing P/E Ratio-2.48
Forward P/E Ratio-2.24
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.11 million
Price / Sales79.46
Cash FlowN/A
Price / CashN/A
Book Value$4.28 per share
Price / Book1.68
Profitability
EPS (Most Recent Fiscal Year)($2.90)
Net Income$-60,800,000.00
Net Margins-3,190.51%
Return on Equity-80.35%
Return on Assets-59.12%
Miscellaneous
Employees44
Outstanding Shares23,350,000
Market Cap$164.42 million
Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions
What is Syndax Pharmaceuticals' stock symbol?
Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."
How were Syndax Pharmaceuticals' earnings last quarter?
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) issued its earnings results on Tuesday, August, 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.87) by $0.13. The company earned $0.38 million during the quarter, compared to analysts' expectations of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 80.35% and a negative net margin of 3,190.51%. View Syndax Pharmaceuticals' Earnings History.
When is Syndax Pharmaceuticals' next earnings date?
What price target have analysts set for SNDX?
3 brokerages have issued 12 month price targets for Syndax Pharmaceuticals' shares. Their predictions range from $24.00 to $40.00. On average, they anticipate Syndax Pharmaceuticals' stock price to reach $31.3333 in the next year. This suggests a possible upside of 336.4% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.
What is the consensus analysts' recommendation for Syndax Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.
What are Wall Street analysts saying about Syndax Pharmaceuticals stock?
Here are some recent quotes from research analysts about Syndax Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Valuation: We base our $30 price target on probability-adjusted revenue forecasts for entinostat in combination with other drugs in advanced HR+, HER2- breast cancer, NSCLC, and metastatic melanoma. We use the net present value of our revenue forecast through 2027, apply a 35% POS for HR+, HER2- breast cancer, and 10% POS for NSCLC and melanoma, with a 3x price/sales multiple, and we value the early stage pipeline at $10 million, the amount of the upfront payments the company made to acquire the menin inhibitors and SNDX-6352, to arrive at our price target." (7/12/2018)
- 2. According to Zacks Investment Research, "Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. " (5/15/2018)
Who are some of Syndax Pharmaceuticals' key competitors?
Some companies that are related to Syndax Pharmaceuticals include Abeona Therapeutics (ABEO), Urogen Pharma (URGN), Viking Therapeutics (VKTX), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), AC Immune (ACIU), Progenics Pharmaceuticals (PGNX), Dova Pharmaceuticals (DOVA), Eidos Therapeutics (EIDX), Verastem (VSTM), Collegium Pharmaceutical (COLL), Prothena (PRTA), ArQule (ARQL), ChemoCentryx (CCXI) and Homology Medicines (FIXX).
Who are Syndax Pharmaceuticals' key executives?
Syndax Pharmaceuticals' management team includes the folowing people:
- Dr. Briggs W. Morrison, CEO & Director (Age 58)
- Mr. Michael A. Metzger, Pres & COO (Age 47)
- Mr. Richard P. Shea, CFO & Treasurer (Age 66)
- Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 67)
- Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 49)
When did Syndax Pharmaceuticals IPO?
(SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
Has Syndax Pharmaceuticals been receiving favorable news coverage?
Press coverage about SNDX stock has trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a media and rumor sentiment score of 0.11 on Accern's scale. They also gave news articles about the company an impact score of 46.87 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Syndax Pharmaceuticals.
Who are Syndax Pharmaceuticals' major shareholders?
Syndax Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.76%), Dimensional Fund Advisors LP (2.26%), Stonepine Capital Management LLC (0.85%), Macquarie Group Ltd. (0.77%), Millennium Management LLC (0.64%) and Bank of New York Mellon Corp (0.33%). View Institutional Ownership Trends for Syndax Pharmaceuticals.
Which institutional investors are selling Syndax Pharmaceuticals stock?
Which institutional investors are buying Syndax Pharmaceuticals stock?
SNDX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Stonepine Capital Management LLC, Macquarie Group Ltd., Dimensional Fund Advisors LP, Algert Global LLC, Aviva PLC, Los Angeles Capital Management & Equity Research Inc. and GSA Capital Partners LLP. View Insider Buying and Selling for Syndax Pharmaceuticals.
How do I buy shares of Syndax Pharmaceuticals?
Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syndax Pharmaceuticals' stock price today?
One share of SNDX stock can currently be purchased for approximately $7.18.
How big of a company is Syndax Pharmaceuticals?
Syndax Pharmaceuticals has a market capitalization of $164.42 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.
How can I contact Syndax Pharmaceuticals?
Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]
MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
